|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| BARDA receivables | ||||||||||||||||||||
| Prepaids and other current assets | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Corporate-owned life insurance ("COLI") asset | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued wages and fringe benefits | ||||||||||||||||||||
| Loan facility | ||||||||||||||||||||
| Current non-qualified deferred compensation ("NQDC") liability | ||||||||||||||||||||
| Contingent liability | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Loan facility - long-term | ||||||||||||||||||||
| Non-qualified deferred compensation liability | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Operating lease liabilities, long term | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Contingent liability, long-term | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Non-qualified deferred compensation plan share awards | ||||||||||||||||||||
| Stockholders' equity (deficit): | ||||||||||||||||||||
| Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 30,926,847 and 30,571,662, shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Company common stock held by the non-qualified deferred compensation plan | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| Total liabilities and stockholders' equity (deficit) | ||||||||||||||||||||
Loading...
